Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Astrazeneca Pharma India Ltd

ASTRAZEN.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: N/A

Last Close

$81.23

▼ -0.51%

Market Cap $2.03B · Vol 5.62K

Key Metrics

P/E Ratio

114.27

FWD: N/A

Market Cap

$2.03B

Mid Cap

Div Yield

0.46%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

33.85

Momentum

Beta

0.86

vs Market

52W High

$103.20

26.85% below

52W Low

$79.12

0.30% above

Volume

5.62K

Avg 11.54K

P/B

22.24

Price-to-book

ROE

N/A

Return on equity

Free Float

18.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Astrazeneca Pharma India Ltd (ASTRAZEN.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ASTRAZEN.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.35%

-5.43%

-7.17%

-13.07%

YTD

-14.13%

-6.75%

+70.67%

+142.57%

Financials & Valuation

TTM · Annual

Total Revenue	$243.49M
Net Income	$20.06M
Revenue Growth (YoY)	+29.73%
Gross Margin	33.20%
Operating Margin	10.27%
Net Profit Margin	8.24%
ROE	N/A
ROA · ROIC	14.38% · 21.32%

P/E Ratio	114.27
Forward P/E (FY1)	N/A
PEG Ratio	1.67
P/S	8.53
P/B	22.24
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	25.00M

Technical Indicators

50-Day SMA	$85.96
200-Day SMA	$89.89
RSI (14)	33.85
Beta	0.86
52-Week High	$103.20
52-Week Low	$79.12

Volume Today	5.62K
Avg Daily Volume (30D)	11.54K
Relative Volume	0.49x
Volatility (10D)	20.20
Volatility (30D)	19.16
Free Float	18.42%

Analyst Consensus

N/A

Current Price $81.23

Mean Target N/A

52W Low$79.12 52W High$103.20

Current

Target

$79.12 $103.20

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE India

FIGIBBG001S82V80

ISININE203A01020

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).